A Pilot Study of Immune Checkpoint Inhibition (Durvalumab With or Without Tremelimumab) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer
Phase of Trial: Phase I/II
Latest Information Update: 13 Mar 2018
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab
- Indications Pancreatic cancer
- Focus Adverse reactions
- 09 Mar 2018 Protocol was amended as Phase 2 has been added and factorial assignment has been changed to sequential assignment.
- 09 Mar 2018 Planned End Date changed from 30 Apr 2018 to 31 Dec 2019.
- 09 Mar 2018 Planned primary completion date changed from 30 Apr 2018 to 31 Dec 2019.